for the latter.

Step 2: Generating a EudraCT Number

The EudraCT number is the unique identifier required on all EU clinical trial documentation. It is created via:

1. Visit https://eudract.ema.europa.eu
2. Navigate to “Create EudraCT Number” and complete the mandatory fields:
   • Study type: interventional or non-interventional
   • Sponsor details: legal name, address, country
   • Trial scope: single-country or multi-country
   • Product classification: chemical, biological, gene therapy, etc.
3. After submission, a system-generated EudraCT number (e.g., 2023-001234-89) is displayed and emailed to the registered contact.

This number must be included in the protocol, subject information leaflet, and ethics committee documents.

Step 3: Completing the Clinical Trial Application (CTA)

The core of EudraCT registration lies in the creation of an XML-based CTA dossier containing two major components:

• Part I: Common across all member states; includes trial design, IMP details, risk-benefit assessment, and safety monitoring
• Part II: Country-specific; includes informed consent forms, investigator CVs, ethics committee documentation, recruitment materials, etc.

Tools such as the EudraCT Clinical Trial Module and EudraCT XML Generator can assist in ensuring that files are formatted correctly. Part I is prepared by the sponsor, while Part II often requires input from local affiliates or CROs.

Step 4: Validating and Uploading the EudraCT Package

Once the dossier is prepared:

1. Run validation tools provided by EMA to check for XML schema errors
2. Address all critical and major warnings prior to submission
3. Log into the EudraCT system using EMA credentials
4. Upload Part I and Part II documents along with supporting PDFs (e.g., protocol, IMPD)
5. Lock and electronically sign the submission package before final submission to National Competent Authorities (NCAs)

At this stage, the trial becomes visible in the EudraCT registry and will eventually sync with the EU Clinical Trials Register (EU-CTR).

Step 5: Submitting to Ethics Committees and NCAs

Following EudraCT upload, sponsors must file the application dossier with:

• National Competent Authorities (NCAs): Each EU country has its own submission portal and timeline
• Ethics Committees (ECs): Local IRBs must approve both scientific and ethical aspects

Submission formats may vary between countries. While the EU Clinical Trials Regulation aims to harmonize this process via CTIS, many trials still rely on EudraCT as the foundational registry. Coordination between regulatory and clinical teams is key to ensuring timely approvals in multiple jurisdictions.

For detailed CTA submission SOPs and timelines, browse regulatory insights at PharmaSOP.in.

Step 6: Post-Registration Requirements and Updates

Once registered, sponsors are obligated to maintain the accuracy of the EudraCT entry by updating key trial milestones:

• Start of Recruitment: Must be updated upon first subject enrolled
• Substantial Amendments: e.g., protocol version updates, safety changes, PI replacement
• Temporary Halt or Early Termination: Must be flagged with justification
• Results Upload: Summary results must be submitted within 12 months of trial completion (6 months for pediatric trials)

Failure to meet these obligations can result in public transparency gaps, EMA inquiries, or non-compliance warnings. It is advisable to assign clear internal responsibilities for registry maintenance.

Common Pitfalls and How to Avoid Them

Based on audit findings and sponsor experiences, here are common mistakes observed:

• Incorrect country selection leading to rejections
• Mismatched version numbers across protocol and EudraCT form
• Unvalidated XML files that cause portal errors
• Missing pediatric compliance section for applicable trials
• Failure to register non-commercial trials under the assumption that it’s not mandatory

Each of these issues can delay CTA approvals or result in administrative queries. QA teams should conduct a final review using a checklist aligned with EMA registry guidance. You can find sample checklists at PharmaValidation.in.

Comparison with CTIS and ClinicalTrials.gov

While EudraCT remains in use, the EU Clinical Trials Information System (CTIS) under CTR (EU) No 536/2014 is now the future-forward platform for unified CTA submissions. Key differences include:

Feature	EudraCT	CTIS
Registry Platform	EudraCT	CTIS
Scope	Directive 2001/20/EC	Regulation 536/2014
Submission Process	Country-wise CTA	Single portal CTA
Result Disclosure	Manually updated	Automated integration

For sponsors with global programs, it’s also necessary to register in ClinicalTrials.gov or WHO ICTRP, depending on trial footprint and funding.

Conclusion

The EudraCT registration process is an integral part of the regulatory lifecycle for clinical trials in Europe. Beyond a regulatory obligation, it reflects a commitment to transparency, subject protection, and scientific integrity. By following a structured SOP, validating files rigorously, and coordinating closely with local stakeholders, sponsors can ensure efficient and compliant registrations.

To explore EU trial disclosure templates and get guidance on transitioning to CTIS, visit EMA’s official site or learn from real sponsor experiences at ClinicalStudies.in.